BioSpace News Archive

HiFiBiO Therapeutics is presenting its three lead pipeline programs at the American Association for Cancer Research (AACR) Virtual Annual Meeting II taking place today. The company is a pioneer of novel antibody drug disc

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share poster presentations of interim data from the ongoing phase II study of paxalisib (formerly GDC-0084) in glioblastoma, the most common and most aggressive form of primary brain cancer, and from the phase I study of Can

F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of innovat

Post-hospitalized patients, especially recently discharged coronavirus disease 2019 (COVID-19) patients, are at higher risk for major thromboembolic events or the formation of blood clots that could lead to death

BioSig Technologies, Inc. and its subsidiary, ViralClear Pharmaceuticals, Inc., announced that it has signed an agreement with Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, to work on the development of a potential treatment for adults with advanced Coronavirus Disease 2019.

Roseman University of Health Sciences President Dr. Renee Coffman has appointed Pedro “Joe” Greer, Jr., MD as dean of the Roseman University College of Medicine.

LGC SeraCare has released the AccuSet™ SARSCoV-2 Performance Panel (material #0820-0410), intended for use by clinical laboratories and diagnostic manufacturers alike, to evaluate SARS-CoV-2 antibody assays.

An essential part of scientific training is learning to communicate new findings in manuscripts and theses. But access to scientific writing training, mentoring, and support varies widely, and many early career scientists report a need for more intensive help in developing their skills.

Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced results from a study that provides preclinical proof-of-concept for combining VS-6766, its RAF/MEK inhibitor, with defactinib, its focal adhesion kinase (FAK) inhibitor,

LeMaitre Vascular, Inc. announced that it has acquired the business and assets of Artegraft, Inc. for $90.0 million, including $72.5 million in cash paid at closing as well as potential earnout payments of $17.5 million payable based upon future sales of the acquired business.